Irving L. Weissman

Irving L. Weissman

Top Cited Scholar 2026
Auto-generated profile, based on publicly available information

Irving L. Weissman

Stanford University

Research Focus & Metrics

Academic Career Length

36Years (1991-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 November 2001 in Nature
Verified
Journal Article
Closed access
PDF file
TRTannishtha Reya
Tannishtha Reya
SMSean J. Morrison
Sean J. Morrison
MCMichael F. Clarke
Michael F. Clarke
IWIrving L. Weissman
Irving L. Weissman

16 January 2007 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
PDF file
MPM. E. Prince
M. E. Prince
RSR. Sivanandan
R. Sivanandan
AKA. Kaczorowski
A. Kaczorowski
GWG. T. Wolf
G. T. Wolf
MKM. J. Kaplan
M. J. Kaplan
LAL. E. Ailles
L. E. Ailles
Like many epithelial tumors, head and neck squamous cell carcinoma (HNSCC) contains a heterogeneous population of cancer cells. We developed an immunodeficient mouse model to test the tumorigenic potential of different populations of cancer cells derived from primary, unmanipulated human HNSCC samples. We show that a minority population of CD44 + cancer cells, which typically comprise <10% of the cells in a HNSCC tumor, but not the CD44 − cancer cells, gave rise to new tumors in vivo . Immunohistochemistry revealed that the CD44 + cancer cells have a primitive cellular morphology and costain with the basal cell marker Cytokeratin 5/14, whereas the CD44 − cancer cells resemble differentiated squamous epithelium and express the differentiation marker Involucrin. The tumors that arose from purified CD44 + cells reproduced the original tumor heterogeneity and could be serially passaged, thus demonstrating the two defining properties of stem cells: ability to self-renew and to differentiate. Furthermore, the tumorigenic CD44 + cells differentially express the BMI1 gene, at both the RNA and protein levels. By immunohistochemical analysis, the CD44 + cells in the tumor express high levels of nuclear BMI1, and are arrayed in characteristic tumor microdomains. BMI1 has been demonstrated to play a role in self-renewal in other stem cell types and to be involved in tumorigenesis. Taken together, these data demonstrate that cells within the CD44 + population of human HNSCC possess the unique properties of cancer stem cells in functional assays for cancer stem cell self-renewal and differentiation and form unique histological microdomains that may aid in cancer diagnosis.

18 November 2020 in Nature
Verified
Journal Article
Closed access
PDF file
KTKyle J. Travaglini
Kyle J. Travaglini
ANAhmad N. Nabhan
Ahmad N. Nabhan
LPLolita Penland
Lolita Penland
RSRahul Sinha
Rahul Sinha
AGAstrid Gillich
Astrid Gillich
MKMark A. Krasnow
Mark A. Krasnow

26 March 2012 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
PDF file
SWStephen B. Willingham
Stephen B. Willingham
JVJens-Peter Volkmer
Jens-Peter Volkmer
AGAndrew J. Gentles
Andrew J. Gentles
DSDebashis Sahoo
Debashis Sahoo
PDPiero Dalerba
Piero Dalerba
IWIrving L. Weissman
Irving L. Weissman
CD47, a “don't eat me” signal for phagocytic cells, is expressed on the surface of all human solid tumor cells. Analysis of patient tumor and matched adjacent normal (nontumor) tissue revealed that CD47 is overexpressed on cancer cells.CD47mRNA expression levels correlated with a decreased probability of survival for multiple types of cancer. CD47 is a ligand for SIRPα, a protein expressed on macrophages and dendritic cells. In vitro, blockade of CD47 signaling using targeted monoclonal antibodies enabled macrophage phagocytosis of tumor cells that were otherwise protected. Administration of anti-CD47 antibodies inhibited tumor growth in orthotopic immunodeficient mouse xenotransplantation models established with patient tumor cells and increased the survival of the mice over time. Anti-CD47 antibody therapy initiated on larger tumors inhibited tumor growth and prevented or treated metastasis, but initiation of the therapy on smaller tumors was potentially curative. The safety and efficacy of targeting CD47 was further tested and validated in immune competent hosts using an orthotopic mouse breast cancer model. These results suggest all human solid tumor cells require CD47 expression to suppress phagocytic innate immune surveillance and elimination. These data, taken together with similar findings with other human neoplasms, show that CD47 is a commonly expressed molecule on all cancers, its function to block phagocytosis is known, and blockade of its function leads to tumor cell phagocytosis and elimination. CD47 is therefore a validated target for cancer therapies.

31 July 2019 in Nature
Verified
Journal Article
Closed access
PDF file
ABAmira A. Barkal
Amira A. Barkal
RBRachel E. Brewer
Rachel E. Brewer
MMMaxim Markovic
Maxim Markovic
MKMark Kowarsky
Mark Kowarsky
SBSammy A. Barkal
Sammy A. Barkal
IWIrving L. Weissman
Irving L. Weissman

20 June 2005 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
DRDerrick J. Rossi
Derrick J. Rossi
DBDavid Bryder
David Bryder
JZJacob M. Zahn
Jacob M. Zahn
HAHenrik Ahlenius
Henrik Ahlenius
RSRebecca Sonu
Rebecca Sonu
IWIrving L. Weissman
Irving L. Weissman
Loss of immune function and an increased incidence of myeloid leukemia are two of the most clinically significant consequences of aging of the hematopoietic system. To better understand the mechanisms underlying hematopoietic aging, we evaluated the cell intrinsic functional and molecular properties of highly purified long-term hematopoietic stem cells (LT-HSCs) from young and old mice. We found that LT-HSC aging was accompanied by cell autonomous changes, including increased stem cell self-renewal, differential capacity to generate committed myeloid and lymphoid progenitors, and diminished lymphoid potential. Expression profiling revealed that LT-HSC aging was accompanied by the systemic down-regulation of genes mediating lymphoid specification and function and up-regulation of genes involved in specifying myeloid fate and function. Moreover, LT-HSCs from old mice expressed elevated levels of many genes involved in leukemic transformation. These data support a model in which age-dependent alterations in gene expression at the stem cell level presage downstream developmental potential and thereby contribute to age-dependent immune decline, and perhaps also to the increased incidence of leukemia in the elderly.